who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...

GSK claims to investors that its decision to remove Zantac from the market was "based on information available at the time and correspondence with regulators," and that the Company was "continuing ...

who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users. The truth began to emerge on August 10, 2022, when a Deutsche Bank ...

The investors are seeking a jury trial and damages ... Boehringer Ingelheim. In key win for GSK, Delaware court will review decision to allow expert testimony in Zantac cases In 2020, after ...

Robbins LLP is Investigating Allegations that GSK PLC (GSK) Misled Investors Regarding its Recall of Zantac According to the complaint, in September and October 2019, GSK suspended its ...

Last year, GSK reported nearly halving its net profit after settling hefty US lawsuits over its Zantac heartburn drug. Net income after tax dropped to £2.6 billion ($3.3 billion) as compared with ...

According to the complaint, in September and October 2019, GSK suspended its distribution of Zantac and initiated a voluntary recall. In April 2020, the FDA requested that manufacturers cease ...

In September and October 2019, GSK suspended its distribution of Zantac (the brand name for the drug ranitidine) and issued a voluntary recall after studies demonstrated that, by interacting with ...

who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users. When the true details entered the market, the lawsuit claims that ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...